Literature DB >> 12930304

Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis.

Claudio Feliciani1, Paola Toto, Binghe Wang, Daniel N Sauder, Pierluigi Amerio, Antonio Tulli.   

Abstract

The role of urokinase type plasminogen activator (uPA) has been well documented in the pathogenesis of pemphigus vulgaris (PV). Activation of plasminogen into active serine protease plasmin initiates extracellular proteolysis leading to acantholysis but the mechanisms underlying this process are not clearly understood. We have previously shown that keratinocyte derived cytokines IL-1alpha and TNF-alpha are involved in PV-induced acantholysis. In the present study we sought to examine whether keratinocyte-derived IL-1alpha and TNF-alpha are correlated with uPA induction in keratinocytes during acantholysis. Normal human keratinocytes were incubated with diluted PV serum. mRNAs for IL-1alpha, TNF-alpha and uPA were examined with RT-PCR at various time points and acantholysis was measured. IL-1alpha, TNF-alpha and uPA mRNAs were all induced in keratinocytes following PV serum stimulation; IL-1alpha/TNF-alpha mRNAs' expression was earlier than the expression of uPA mRNA. To further examine the role of IL-1alpha, TNF-alpha and uPA in acantholysis, we performed antibody blocking studies. Anti-IL-1alpha, anti-TNF-alpha and anti-uPA antibodies suppressed acantholysis by 76%, 80% and 90%, respectively. In addition, anti-IL-1alpha and anti-TNF-alpha antibodies inhibited uPA mRNA induction, whereas anti-uPA antibodies did not alter IL-1alpha/TNF-alpha mRNAs' expression. Our results confirm the role of uPA in acantholysis and suggest an involvement of IL-1alpha/TNF-alpha in uPA induction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12930304     DOI: 10.1034/j.1600-0625.2002.120415.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  13 in total

Review 1.  [Pemphigus. Model disease for targeted therapy].

Authors:  R Eming
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

2.  Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus.

Authors:  Juan Arredondo; Alexander I Chernyavsky; Ali Karaouni; Sergei A Grando
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

3.  A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone.

Authors:  R P Hall; J Fairley; D Woodley; V P Werth; D Hannah; R D Streilein; J McKillip; J Okawa; M Rose; L L Keyes-Elstein; A Pinckney; A Overington; J Wedgwood; L Ding; B Welch
Journal:  Br J Dermatol       Date:  2015-02-05       Impact factor: 9.302

4.  Antimitochondrial autoantibodies in pemphigus vulgaris: a missing link in disease pathophysiology.

Authors:  Steve Marchenko; Alexander I Chernyavsky; Juan Arredondo; Vivian Gindi; Sergei A Grando
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

5.  Endemic pemphigus over a century: Part II.

Authors:  Ana María Abréu-Vélez; Ana Maria Roselino; Michael S Howard; Iara J de Messias Reason
Journal:  N Am J Med Sci       Date:  2010-03

6.  Pathogenic activity of circulating anti-desmoglein-3 autoantibodies isolated from pemphigus vulgaris patients.

Authors:  Joanna Narbutt; Joanna Boncela; Katarzyna Smolarczyk; Cezary Kowalewski; Katarzyna Wozniak; Jolanta Dorota Torzecka; Anna Sysa-Jedrzejowska; Czesław S Cierniewski; Aleksandra Lesiak
Journal:  Arch Med Sci       Date:  2012-05-09       Impact factor: 3.318

Review 7.  The desmosome and pemphigus.

Authors:  Jens Waschke
Journal:  Histochem Cell Biol       Date:  2008-04-03       Impact factor: 4.304

8.  Mechanisms of foot-and-mouth disease virus tropism inferred from differential tissue gene expression.

Authors:  James J Zhu; Jonathan Arzt; Michael C Puckette; George R Smoliga; Juan M Pacheco; Luis L Rodriguez
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

9.  Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris.

Authors:  Joanna Narbutt; Jolanta Lukamowicz; Jarosław Bogaczewicz; Anna Sysa-Jedrzejowska; Jolanta Dorota Torzecka; Aleksandra Lesiak
Journal:  Mediators Inflamm       Date:  2008       Impact factor: 4.711

10.  A retrospective study of antihypertensives in pemphigus: a still unchartered odyssey particularly between thiols, amides and phenols.

Authors:  Paweł Pietkiewicz; Justyna Gornowicz-Porowska; Monika Bowszyc-Dmochowska; Marian Dmochowski
Journal:  Arch Med Sci       Date:  2015-10-12       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.